Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Noninvasive Biomarkers of Asthma (CROSBI ID 61594)

Prilog u knjizi | stručni rad | međunarodna recenzija

Mirjana Turkalj, Damir Erceg, Iva Dumbović Dubravčić Noninvasive Biomarkers of Asthma // Asthma Diagnosis and Menagement / Kuan-Hsiang Gary Huang, Chen Hsuan Sherry Tsai (ur.). London : Delhi: IntechOpen, 2018. str. 3-19

Podaci o odgovornosti

Mirjana Turkalj, Damir Erceg, Iva Dumbović Dubravčić

engleski

Noninvasive Biomarkers of Asthma

Asthma is a heterogeneous disease of the lower airways including various types of bronchial inlammation presenting with diferent phenotypes and endotypes. Therapeutic response of asthmatic phenotypes/endotypes can be predicted by the use of biomarkers of inlammation phenotyping, and in recent years, endotyping of asthmatics allows to predict who will best respond to anti-inlammatory treatment and optimize quality of life of asthmatics by reducing the risk of exacerbations. Based on noninvasive biomarkers of inlammations, several of them have been described that are useful in clinical practice. Some of the noninvasive biomarkers have a particularly important role in the diagnosis and treatment of asthmatics. Monitoring of noninvasive biomarkers, such as fraction of exhaled nitric oxide (FENO), cells in sputum, or biomarkers in exhaled breath condensate (EBC), two main inlammatory phenotypes have been described: eosinophilic phenotype and neutrophilic phenotype. In eosinophilic asthma, as the most prevalent inlammatory phenotype, asthmatics have more than 3% eosinophils in the sputum, elevated levels of FENO, and elevated leukotriene’s cytokine levels in EBC. The most extensively studied biomarkers in asthma are TH2 or more generally T2-related asthmatic endotype. Their clinical beneit might be used to phenotype/endotype features of the underlying type of inlammation and selection of asthmatics, particularly with severe or diicult-to-treat asthma, which most likely will respond to additional biological therapy. In this chapter, we summarize the noninvasive biomarkers available for the management of asthmatics.

asthma, biomarker, inlammation, phenotype, endotype

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

3-19.

objavljeno

Podaci o knjizi

Asthma Diagnosis and Menagement

Kuan-Hsiang Gary Huang, Chen Hsuan Sherry Tsai

London : Delhi: IntechOpen

2018.

978-1-78923-322-3

Povezanost rada

Kliničke medicinske znanosti